Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Olaparib + PLD in Platinum-Resistant Ovarian Cancer
2016-004850-14Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Sep 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and doxorubicin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: 6-month progression-free survival rate (PFS6m). Started Sep 2017; status: completed.
02
Drugs
olaparibdoxorubicin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2016-004850-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004850-14.